# Rivastigmine

Source: https://onco.cc/drugs/da-rivastigmine/  
OnCo record `da-rivastigmine` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Rivastigmine is used for Alzheimer’s dementia and has a US indication for dementia associated with Parkinson’s disease. It is a symptom treatment.

## Summary

Patch and capsules exist. Gastrointestinal effects and patch-site reactions matter in frail people. It is not a disease-modifying Lewy body treatment.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Brand: Exelon
- Modality: small molecule
- Mechanism: Cholinesterase inhibitor, oral or patch.
- Approvals: US 2000: Alzheimer’s dementia; Parkinson’s disease dementia; EU 1998: Alzheimer’s dementia; UK 1998: Alzheimer’s dementia; JP 2011: Alzheimer’s dementia; CN 2000: Alzheimer’s dementia; AU 2000: Alzheimer’s dementia

## Sources

- Alzheimer’s Association: medicines for cognition: https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/), [Dementia with Lewy bodies](https://onco.cc/diagnoses/dementia-with-lewy-bodies/), [Parkinson’s disease dementia](https://onco.cc/diagnoses/parkinsons-disease-dementia/)
- targets: [Acetylcholinesterase](https://onco.cc/targets/da-target-ache/)
- technologies: [Cholinesterase inhibitors](https://onco.cc/technologies/da-tech-cholinesterase-inhibitors/)

---
JSON: https://onco.cc/api/v1/entities/da-rivastigmine.json